至于说这个新公司的管理问题，据说马里斯一开始就想着要来管理它，同时却又保持自己在谷歌创投中的位置（有点像杰克•多西所做的那样）。不过他也广泛征求各方意见，请求推荐首席执行官的人选。马里斯求教的人中就有阿特•列文森，他居然真的打算加盟，这真是让人大跌眼镜（如果大家没把他看成是已经从首席管理层岗位上彻底引退的话，他却也是这个职位的不二人选）。

    列文森已经开始为新公司物色人选了。在硅谷的一些人看来，这家公司更像是一家要做长期研究的机构，而不是那种几年里就准备上临床试验的生物制药初创企业。随着更多人开始准备为Calico公司效力（或是打算这么做），我们也会了解到更多情况。

    不过现在我们掌握的情况是，这家公司不差钱，比多数大型药企都更灵活，而且在谷歌最终操盘前，它还吸引了众多业界知名的投资机构的关注。再者，它的掌门人是一位多数生命科学企业会不惜一切代价都想聘请的高人。所以说，它的开局还真是不赖。（财富中文网）

    译者：清远  

    As for management, Maris is said to have originally thought about helping to run the new company, while also maintaining his Google Ventures role (kind of a Jack Dorsey sort of thing). But he also reached out to various folks to get names for prospective CEOs. Among those from whom he sought advice was Art Levinson, who surprisingly threw his own hat into the ring (and would have been the obvious choice for this sort of thing, if everyone hadn't viewed him as permanently retired from the C-suite).

    Levinson already has begun interviewing people for positions at Calico, which some in the Valley are viewing as more of a long-term research institute than a biopharma startup that will be in clinical trials within a couple of years. As more people begin to work at Calico (or at least try to), we'll likely learn more about it.

    For now, however, what we know is that the effort is very well-funded with more flexibility than most big pharma, and that it was appealing to a wide swath of respected investors before Google swept in. Plus, it's led by someone who most other life sciences companies would have given their left lab to hire. Not a bad start…